These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7437348)

  • 21. Editorial: Clinical concentrates of clotting-factor IX.
    Lancet; 1975 Nov; 2(7940):855-6. PubMed ID: 53334
    [No Abstract]   [Full Text] [Related]  

  • 22. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
    Verroust F; Moussard C; Allain JP
    Presse Med; 1985 May; 14(19):1073-6. PubMed ID: 3158962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and properties of a therapeutic factor IX concentrate.
    Suomela H; Myllylä G; Raaska E
    Vox Sang; 1977 Jul; 33(1):37-50. PubMed ID: 883244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.
    Franchini M; Makris M; Santagostino E; Coppola A; Mannucci PM
    Haemophilia; 2012 May; 18(3):e164-72. PubMed ID: 22250981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The response of an acquired Factor V inhibitor to activated Factor IX concentrate.
    Vickars LM; Coupland RW; Naiman SC
    Transfusion; 1985; 25(1):51-3. PubMed ID: 3871542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Reflections on the use of PPSB fraction (Prothrombin-proconvertin-Stuart factor-antihemophilic factor B)].
    Malinvaud G
    Transfusion (Paris); 1966; 9(3):245-54. PubMed ID: 5969560
    [No Abstract]   [Full Text] [Related]  

  • 27. Von Willebrand disease within the collective of haemophilic patients as reason for unexpected bleeding episodes.
    Siegmund B; Richter H; Pollmann H
    Haemophilia; 2007 Jan; 13(1):21-5. PubMed ID: 17212720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.
    Lancet; 1988 Oct; 2(8615):814-6. PubMed ID: 2902265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Gene therapy of haemophilia - has the cure come within reach?].
    Kaczmarek R
    Postepy Biochem; 2018 Dec; 64(4):318-322. PubMed ID: 30656916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myocardial infarction during factor IX infusion in hemophilia B: case report and review of the literature.
    Najaf SM; Malik A; Quraishi AU; Kazmi K; Kakepoto GN
    Ann Hematol; 2004 Sep; 83(9):604-7. PubMed ID: 15205916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
    Pollmann H
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.
    Parry DH; Bloom AL
    J Clin Pathol; 1978 Nov; 31(11):1102-5. PubMed ID: 739057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [On the therapy of bleeding tendency due to vitamin K deficiency and dysfunction of the liver during the first year of life. (Combined treatment with a concentrate of factors II, VII, IX and X and heparin) (author's transl)].
    Göbel U; Petrich C
    Monatsschr Kinderheilkd (1902); 1974 Feb; 122(2):60-4. PubMed ID: 4594807
    [No Abstract]   [Full Text] [Related]  

  • 34. Factor IX and thrombosis.
    Aledort LM
    Scand J Haematol Suppl; 1977; 30():40-2. PubMed ID: 267296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
    Kraiem I; Hadhri S; El Omri H; Sassi R; Chaabani W; Ennabli S; Skouri H
    Ann Biol Clin (Paris); 2012; 70(6):659-65. PubMed ID: 23207810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy in viral inactivation of the concentrates of factor VIII and IX by the solvent/detergent procedure. Evaluation in patients with hemophilia].
    Guerois C; Parquet A; Vicariot M; Lecoeur FF; Maisonneuve P; Courouce AM; Dubois F; Laurian Y
    Presse Med; 1991 Jun; 20(25):1163-6. PubMed ID: 1830653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coronary bypass in a patient with hemophilia B, or Christmas disease. Case report.
    Tourbaf KD; Bettigole RE; Zizzi JA; Subramanian S; Andersen MN
    J Thorac Cardiovasc Surg; 1979 Apr; 77(4):562-9. PubMed ID: 311396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prothrombin concentrates in treatment of Christmas disease and allied disorders.
    Breen FA; Tullis JL
    JAMA; 1969 Jun; 208(10):1848-52. PubMed ID: 5818828
    [No Abstract]   [Full Text] [Related]  

  • 39. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.